Adoptive cell therapy utilizes a patient's own cells to fight against diseases like cancer. This therapy involves extracting T-cells or immune cells from a patient's blood and modifying them genetically to recognize and attack cancer cells. These modified T-cells are then infused back into the patient to trigger an anti-tumor immune response. With increasing investment in research and development of novel CAR T-cell and TIL therapies, adoptive cell therapy has shown promising results in treating various oncological conditions.

The global Adoptive Cell Therapy Market is estimated to be valued at US$ 6,903.93 Mn in 2023 and is expected to exhibit a CAGR of 4.8% over the forecast period from 2024 to 2031, as highlighted in a new report published by Coherent Market Insights.

Market key trends:
Rising research and development activities is one of the key trends driving growth of the adoptive cell therapy market. Manufacturers are focusing on development of next-generation CAR T-cell therapies with enhanced specificity and efficacy. For instance, Johnson & Johnson is developing Liso-cel, a BCMA-directed CAR T-cell therapy for treatment of multiple myeloma. Positive clinical trial results of such novel CAR T therapies will encourage adoption among healthcare facilities and boost market revenue over the forecast period.

Segment Analysis
The global Adoptive Cell Therapy Market is dominated by T-cell therapy sub segment. T-cell therapy involves extracting patients' T cells, modifying them genetically to target specific cancer cells, and then infusing the modified T cells back into the patient's body to fight cancer. T-cell therapy sub segment has captured over 60% of the global market share owing to recent advancements and increasing adoption of CAR-T therapies for cancer treatment.

Key Takeaways
The Global Adoptive Cell Therapy Market Size is expected to witness high growth over the forecast period of 2024 to 2031. The global Adoptive Cell Therapy Market is estimated to be valued at US$ 6,903.93 Mn in 2023 and is expected to exhibit a CAGR of 4.8% over the forecast period from 2024 to 2031.

The North America region currently dominates the market with over 45% share due to presence of advanced healthcare infrastructure and higher adoption of innovative therapies.
The Asia Pacific region is expected to experience the highest growth rate during the forecast period owing to rising healthcare expenditures, increasing cancer incidence, and growing focus of international players to tap growth opportunities. China, India, and Japan are emerging as highly lucrative markets in the region. The growth can also be attributed to increasing patient awareness, rising disposable incomes, and improving healthcare infrastructure in developing APAC countries.

Key players related content:
Key players operating in the Adoptive Cell Therapy market are Broadcom, Celeno Communications, Infineon Technologies, Espressif Systems Shanghai Co Ltd, GCT Semiconductor Inc., I&C Technology, Intel Corporation, MediaTek, Inc., and Microchip Technology Inc. Players are focusing on partnerships for technology advancement and new product launches to strengthen their market position. For instance, Novartis AG received approval for Kymriah, the first CAR-T cell therapy, for the treatment of B-cell ALL in pediatric and young adult patients.

Get more insights on this topic:
https://www.dailyprbulletin.com/adoptive-cell-therapy-insights/